DurAVR ® THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm 2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. At one-year, clinical safety outcomes ...
When targeting hemodynamics for treatment of symptomatic heart failure, the primary physiological determinants of cardiac performance are most easily modulated by pharmacological and mechanical ...
Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), ...
The most tremendous advancements in the field of cardiovascular medicine over the past two decades, I’d argue, have been in the areas of structural heart disease and imaging. In the 1960s and 1970s, ...
At the Bronx Municipal Hospital Center patients having sudden episodes of hypotension when the clinical diagnosis is acute pulmonary embolism are being studied at the bedside by emergency ...
The amount of blood that the heart pumps in one minute (cardiac output) can be directly measured safely in newborns by monitoring changes in blood velocity after injecting saline, indicates a paper ...
Please provide your email address to receive an email when new articles are posted on . Cardiac MRI data suggest acoramidis could improve outcomes for people with symptomatic transthyretin amyloid ...
The diagram shows the way in which triiodothyronine increases cardiac output by affecting tissue oxygen consumption (thermogenesis), vascular resistance, blood volume, cardiac contractility, and heart ...
The etiology of heart failure involves alterations in multiple organ systems and neurohormonal regulatory processes. Table 1 summarizes the pathophysiological mechanisms that are believed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback